Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis

Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis

IntroductionImmune checkpoint inhibitors (ICI) are increasingly being used to treat numerous cancer types. Together with improved recognition of toxicities, this has led to more frequent identification of rare immune-related adverse events (irAE), for which specific treatment strategies are needed....

Full description

Bibliographic Details
Main Authors: Anne Zaremba, Rafaela Kramer, Viola De Temple, Stefanie Bertram, Martin Salzmann, Anja Gesierich, Lydia Reinhardt, Barouyr Baroudjian, Michael M. Sachse, Gunhild Mechtersheimer, Douglas B. Johnson, Alison M. Weppler, Lavinia Spain, Carmen Loquai, Milena Dudda, Claudia Pföhler, Adriana Hepner, Georgina V. Long, Alexander M. Menzies, Matteo S. Carlino, Céleste Lebbé, Tomohiro Enokida, Makoto Tahara, Paul J. Bröckelmann, Thomas Eigentler, Katharina C. Kähler, Ralf Gutzmer, Carola Berking, Selma Ugurel, Nadine Stadtler, Antje Sucker, Jürgen C. Becker, Elisabeth Livingstone, Friedegund Meier, Jessica C. Hassel, Dirk Schadendorf, Maher Hanoun, Lucie Heinzerling, Lisa Zimmer
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
malignant melanoma
immune checkpoint inhibition
adverse events
hematotoxicity
neutropenia
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.765608/full

Similar Items

Similar Items